Research article · 12 Jun 2025
Conference abstractPublished 2017
Nitric oxide-releasing self-assembled nanoparticles as a chemo sensitizing agent for improved anticancer activity
Kyung Hee University, Republic of Korea
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Statement of the Problem: Nitric oxide (NO) plays significant roles as a bioregulatory agent in apoptosis of cancer cells. Recently, it was reported that NO treatment in combination with diverse anticancer drugs, such as doxorubicin and cisplatin, improved their anticancer activity. To date, several classes of NO donors that can store and release NO in a controlled manner have been developed. S-Nitrosoglutathione (GSNO) is preferable over other classes of synthetic NO donors for intracellular NO delivery because it is an endogenous species. However, GSNO has low aqueous stability and insufficient specificity to target tumor tissues after i.v. injection. Thus, it is challenging to develop a delivery system that can efficiently improve stability and tumor-specificity of GSNO molecules. Methodology & Theoretical Orientation: We aim to develop GSNO-conjugated hyaluronic acid-based assembled nanoparticles (GSNO-HANP) and demonstrate that such nanoparticles preferentially generate NO in response to intracellular hyaluronidase-1 (Hyal-1) and intracellular reducing environments. In addition, the combinative effect of NO-releasing nanoparticles on the anticancer activity of doxorubicin (DOX) against MCF-7 human breast cancer cells was examined. Findings: The GSNO-HANP greatly improved stability of GSNO in aqueous phase. The GSNO-HANP triggered NO release at cytosol through Hyal-1-induced degradation of nanoparticles and an intracellular reduction of GSNO by ascorbic acid. In vitro and in vivo experiments demonstrated that NO release by the GSNO-HANP efficiently improved the sensitivity of MCF-7 cells for DOX therapy. Conclusion & Significance: We have developed well-defined GSNO-conjugated hyaluronic acid-based assembled nanoparticles. The nanoparticles improved stability of GSNO in the aqueous phase and efficiently released NO into cytosols. The NO release by the GSNO-HANP in combination with DOX treatment resulted in improved apoptosis of the MCF-7 cells. This intracellular NOreleasing GSNO-HANP may serve as useful chemosensitizing agents to improve therapeutic activities of various anticancer drugs.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Pharmaceutics & Drug Delivery Research.
Research article · 20 Feb 2025
Sustained Drug Delivery in Pharmaceutical Dosage Forms for Novel Approaches of Formulation Design
Research article · 23 Jan 2025
Cutting Out Counterfeits: How Blockchain Can Revolutionize Drug Traceability?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmaceutics & Drug Delivery Research
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Kyung Hyun Min”
- BylineArticles whose byline prints “Da Eun Kim”
- BylineArticles whose byline prints “Hong Jae Lee”
- BylineArticles whose byline prints “Sang Cheon Lee”

